Compare SFM & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFM | DFTX |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | 2013 | 2020 |
| Metric | SFM | DFTX |
|---|---|---|
| Price | $71.94 | $37.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $98.89 | $38.50 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.60 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $8,806,159,000.00 | N/A |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $7.36 | N/A |
| P/E Ratio | $23.85 | ★ N/A |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $64.75 | $14.62 |
| 52 Week High | $127.91 | $49.70 |
| Indicator | SFM | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 37.39 |
| Support Level | $72.37 | $16.37 |
| Resistance Level | $80.46 | $49.13 |
| Average True Range (ATR) | 3.55 | 2.02 |
| MACD | -0.86 | -0.31 |
| Stochastic Oscillator | 12.76 | 0.54 |
Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.